Discovery Lab Answers

Elisabeth Targ, MD was a psychiatrist and clinical researcher whose work sits at an unusual intersection: she brought randomized controlled trial methodology from mainstream medicine to bear on distant healing, a topic that laboratory parapsychology had rarely approached with that level of clinical rigor. The sources retrieved for this question cover her work primarily through the lens of her father Russell Targ‘s writings ^[1][2], with her ESP-Nexus profile providing additional grounding. What follows works through her research record across the four dimensions.

Experiments

Targ’s principal research program investigated distant healing in patients with advanced AIDS, conducted at the California Pacific Medical Center. She ran randomized controlled trials asking whether intentional mental focus directed toward a patient’s wellbeing — by healers who were geographically separated from the patient — could produce measurable improvements in clinical outcomes. These trials represent her core experimental contribution.

Her earlier background included exposure to laboratory psi research through her family connection to the field — her father is physicist and remote-viewing researcher Russell Targ ^[1][2] — but her own scientific identity was built around clinical trial design rather than laboratory paradigms such as ganzfeld or card-guessing protocols.

The retrieved sources do not name specific collaborators on her clinical trials by citation, though her ESP-Nexus profile notes she worked within the California Pacific Medical Center research environment.

Methodology

Targ’s methodological signature was the application of double-blind, randomized controlled trial design to distant healing — a design standard borrowed from pharmaceutical and clinical medicine research and rarely applied to anomalous healing questions at the time.

The core structure of her trials:

• Participants: Patients with advanced AIDS, a population for whom conventional medicine offered limited options during the 1990s, which made measurable clinical endpoints (survival, illness severity, medical utilization) tractable and meaningful.
• Blinding: Double-blind — neither patients nor treating clinicians knew which patients had been assigned to receive distant healing.
• Randomization: Patients were randomly assigned to distant healing or control conditions.
• Healers: Geographically separated from patients; no physical contact or interaction with patients during the trial period.
• Outcome measures: Clinical endpoints drawn from medical records rather than self-report — the kind of hard outcomes that clinical medicine treats as primary.

What distinguished this approach from most parapsychology research of the era was its clinical rather than laboratory orientation: real patients, real illness, real medical records, rather than volunteer subjects in a controlled laboratory environment. The ESP-Nexus profile characterizes this as bringing medical-research standards to the study of anomalous healing effects, at a time when such interdisciplinary work was rare in mainstream medical institutions.

The retrieved sources do not provide granular protocol details — specific healer instructions, session durations, or the exact outcome battery — within the excerpts available here; the primary papers themselves would carry those specifications.

Data

No structured quantitative evidence block was retrieved for this question, and the numbered sources do not contain verified statistics from Targ’s own clinical trials in passages whose surrounding text is intact enough to attribute figures unambiguously to specific outcome measures and conditions. Reporting figures from the retrieved excerpts in that circumstance would risk attaching a number to the wrong claim, which is the one error this project does not absorb.

What the sources do establish at the level of description:

• Her trials measured clinical outcomes in advanced AIDS patients — outcomes drawn from medical records, not laboratory apparatus.
• The design was intended to detect whether distant healing produced measurable differences between randomly assigned groups under double-blind conditions.
• Her ESP-Nexus profile characterizes her as having applied clinical-trial methodology to parapsychology research in a way that was distinctive for the period.

For the actual trial statistics — sample sizes, effect sizes, p-values, direction of results — the retrieved excerpts do not show them, and readers should consult her primary publications directly. The ESP-Nexus page on Elisabeth Targ, MD is the appropriate starting point for sourced figures as the site’s coverage of her work develops.

Skeptical critiques

The numbered sources retrieved for this question do not include published criticism of Targ’s distant healing trials by a named critic with a citable work. Rather than construct a critique section from unattributed background knowledge — which would violate the attribution grounding rules this site applies — this section notes that absence honestly.

What the sources do record is that her work occupied contested interdisciplinary ground: clinical trial methodology applied to a phenomenon that mainstream medicine did not recognize as real. That position invites scrutiny from two directions — parapsychologists examining whether the clinical design was sensitive enough to detect an effect, and medical researchers examining whether the design adequately controlled for placebo, expectancy, and other confounds. Whether any named critic published a formal methodological challenge to her specific trials is not established by the retrieved sources.

Russell Targ’s 2016 essay ^[2] records that she died in July 2002 at age 40, of a brain tumor — her research program was cut short before it could be extended or independently replicated at other sites, which is itself a relevant fact about the state of the record.

For the fullest account of her work and any critical engagement the site has documented, see the Elisabeth Targ, MD page on ESP-Nexus.